Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014

Panato, Chiara; Abusamaan, Khaled; Bidoli, Ettore; Hamdi-Chérif, M.; Pierannunzio, Daniela; Ferretti, Stefano; Daher, Mahmoud; Elissawi, Fouad

doi:10.1186/s12885-018-4552-x

Cited by 20 publications

(25 citation statements)

References 15 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year survival rate varies widely among countries, from 53% in South Africa to 89% in the United States of America [10]. The 5-year survival rate was reported to be 60–65% among Jordanian and Saudi Arabian women [11], 65.1% in the Gaza Strip [12], and 70% in Iran [13]. In return, it is better in developed countries: 82% in Europe [14] and 89% in the USA [15].…”

Section: Introductionmentioning

confidence: 99%

System Delay in Breast Cancer Diagnosis in Gaza Strip, Palestine

Al-Shiekh¹,

Alajerami

Etewa³

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Background Breast cancer is a major public health problem and the first leading cause of cancer deaths among females in Palestine. Early diagnosis of breast cancer contributes to reduction of morbidity and mortality rates. This study aimed to explore system-related factors affecting the timely diagnosis of breast cancer in the Gaza Strip. Method and Materials A mixed method, sequential explanatory design was employed. A quantitative study was conducted first, and it was cross-sectional in nature, followed by a qualitative study. An interviewed questionnaire and an abstraction sheet were used to collect necessary quantitative data among 122 females diagnosed with breast cancer. A purposive sample of five medical specialists were selected for in-depth interview. Descriptive and inferential analyses were used to find differences between variables. Odds ratio and confidence interval at 95% were presented, and P < 0.05 was considered statistically significant. Results Around 12.3% of women experienced diagnostic delay for 3 months and more, and 6.6% reported a delay in referral for more than 2 weeks. Regarding imaging delay, around 8.2% and 2.7% of women had reported a delay in performing mammography and ultrasound, respectively. Moreover, one-fourth reported delay in performing biopsy for more than 14 days, and 46.3% reported delay more than 14 days in getting histopathology report. In addition, 9% missed the follow-up after benign findings of the previous breast imaging and no national protocols are available for the diagnosis of breast cancer in the Gaza strip. Conclusion There is a long appointment time for diagnostic tools especially in biopsy. The nonmalignant findings from mammography or ultrasound could affect diagnosis time. It is an urgent need to have a national protocol for diagnosis and management of breast cancer and to adopt screening, diagnostic, and follow-up programs under the supervision of the Ministry of Health.

show abstract

Section: Introductionmentioning

confidence: 99%

System Delay in Breast Cancer Diagnosis in Gaza Strip, Palestine

Al-Shiekh¹,

Alajerami

Etewa³

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…For patients in the Gaza Strip diagnosed with breast cancer and colon cancer from 2005 to 2014, Panato et al found they had respective 5-year survival rates of 65·1% and 50·2%. These survival rates are comparable to surrounding Arab countries during the same period, but substantially lower than high income Mediterranean countries, such as Italy or among Jewish patients in Israel [ 27 ]. The deteriorating situation in the Gaza Strip in more recent years, with further reductions in the availability of essential medicines adding to long-term lack of services and facilities for particular patient groups, has significant potential implications for the morbidity and mortality of cancer patients.…”

Section: Discussionmentioning

confidence: 82%

Comparative survival of cancer patients requiring Israeli permits to exit the Gaza Strip for health care: A retrospective cohort study from 2008 to 2017

Bouquet¹,

Barone-Adesi

Lafi³

et al. 2021

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Gaza has been under land, sea, and aerial closure for 13 years, during which time Palestinian patients from Gaza have been required to obtain Israeli-issued permits to access health facilities in the West Bank (including east Jerusalem), as well as in Israel and Jordan. Specific groups, like cancer patients, have a high need for permits due to lack of services in Gaza. The approval rate for patient permits to exit Gaza dropped from 94% in 2012 to 54% in 2017. We aimed to assess the impact of access restrictions due to permit denials/delays on all-cause mortality for cancer patients from Gaza referred for chemotherapy and/or radiotherapy. Methods This study matched 17,072 permit applications for 3,816 cancer patients referred for chemotherapy and/or radiotherapy from 1 January 2008 to 31 December 2017 with referrals data for the same period and mortality data from 1 January 2008 to 30 June 2018. We carried out separate analyses by period of first application (2008–14; 2015–17), in light of varying access to Egypt during these times. Primary analysis compared survival of patients according to their first referral decision (approved versus denied/delayed) using Kaplan-Meier method and Cox regression. Findings Mortality in patients unsuccessful in permit applications from 2015–17 was significantly higher than mortality among successful patients, with a hazard ratio of 1·45 (95% CI: 1·19–1·78, p<0.001), after adjusting for age, sex, type of procedure, and type of cancer. There was no significant difference in mortality risk for the two groups in the 2008–2014 period. Interpretation Limitations to patient access due to unsuccessful applications for permits to exit the Gaza Strip had a significant impact on mortality for cancer patients applying for chemotherapy and/or radiotherapy in the period 2015–17. The substantially higher number of annual unsuccessful permit applications from 2015, combined with severely limited alternatives to access chemotherapy and radiotherapy during these years, may be important factors to explain the difference in the impact of permits delays/denials between the two study periods.

show abstract

“…On top of that, multiple antineoplastic medications are not allowed to patients due to prohibition. 12 Even though regular prompt screening and reasonable care to the patient available in most developed countries brings a better outcome, but, many other factors play a significant role. Studies have shown that the outcome of CRC is determined by various factors, including the American Joint Committee on Cancer AJCC staging, tumor location, and neoadjuvant/adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Colorectal cancer prognosis between developed and developing countries: A literature review.

Naik¹

2021

J Asian Med Stud Assoc

View full text Add to dashboard Cite

Background: The cancer is caused when cells start dividing abnormally in the body. Age, genetics and lifestyle are major risk factors in developing cancer. The World Cancer Research Fund states that colorectal cancer incidence is globally ranked third in men and second in women. This highlights the need for effective screening and management of colorectal cancer to achieve better prognosis to prevent mortality and morbidity. Screening and management are not uniform all over the world, and it is affected by the economy of individual countries. In this context, we aimed to explore the prognosis of colorectal cancer in developed and developing countries and also to look for the factors affecting the prognosis.Material and Methods: A systematic search of the peer-reviewed journals from databases at Perdana University library which includes British Medical Journal, Up To Date, The Lancet, and Pubmed was done to answer the research questions. Results: We found that developed countries were in the west having a predominantly Caucasian population. The 5-year survival of patients with colorectal cancer (2008-13) was found to be least in Poland and the highest in Australia. In the developing countries it was found to have a broad representation from different ethnicities. The 5-year survival of colorectal cancer fwas ound to be least in Ghana and highest in Turkey.Conclusion: Looking at the results, the range of prognosis among developed countries is narrower than those in developing countries. This may be due to standardized screening and treatment practice in developed countries.

show abstract

Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014

Cited by 20 publications

References 15 publications

System Delay in Breast Cancer Diagnosis in Gaza Strip, Palestine

System Delay in Breast Cancer Diagnosis in Gaza Strip, Palestine

Comparative survival of cancer patients requiring Israeli permits to exit the Gaza Strip for health care: A retrospective cohort study from 2008 to 2017

Comparison of Colorectal cancer prognosis between developed and developing countries: A literature review.

Contact Info

Product

Resources

About